Videos

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.








Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma  

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

Articles

Brian Van Tine, MD, PhD, discusses what tazemetostat’s approval brings to the treatment landscape for patients with epithelioid sarcoma.

Expert Explains Significance of Tazemetostat FDA Approval for Rare Sarcoma

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Dr. Kahl on Efficacy of Targeted Agents in Relapsed/Refractory Indolent Lymphomas

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Siteman

Latest from Siteman

New content coming soon, please check back later.